regulatory
confidence high
sentiment neutral
materiality 0.80
Atara and Pierre Fabre request FDA Type A meeting for tabelecleucel BLA resubmission
Atara Biotherapeutics, Inc.
- Pierre Fabre submitted Type A meeting request to FDA to address CRL issues for tabelecleucel (EBVALLO) BLA.
- Briefing book argues ALLELE study was adequate; includes updated efficacy data and European post-marketing data.
- FDA Complete Response Letter was issued January 9, 2026; meeting seeks path forward for EBV+ PTLD therapy.
- CEO Cokey Nguyen cites urgent unmet need expressed by PTLD community and physician advocates.